Log in to search using one of your social media accounts:

 

Longer Progression - Free Survival for Durvalumab in NSCLC

Longer median progression - free survival from randomization, higher response rate with durvalumab
Source: Pulmonary Medicine News - Doctors Lounge - Category: Respiratory Medicine Tags: Internal Medicine, Oncology, Pathology, Pharmacy, Pulmonology, Radiology, Surgery, Conference News, Source Type: news

Related Links:

Authors: Wang J, Huang S Abstract Lung cancer is the most prevalent malignant tumor type in the developed world and the discovery of novel anti-tumor drugs is a research hotspot. Fisetin, a naturally occurring flavonoid, has been reported to have anti-cancer effects in multiple tumor types. The present study found that fisetin inhibited the growth and migration of non-small cell lung cancer in vitro. MTT, wound-healing, cell-matrix adhesion and Transwell assays were performed and demonstrated that fisetin suppressed proliferation, migration, adhesion and invasion, respectively. Flow cytometric analysis indicated th...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
ConclusionEBUS TBNA is effective and has a high proportion of satisfactory results for testing PD‐L1 expression on tumor cells in addition to NGS and ALK FISH.
Source: Diagnostic Cytopathology - Category: Pathology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Conditions:   Non-Small Cell Lung Cancer (NSCLC);   Non-Small-Cell Lung Carcinoma;   Nonsmall Cell Lung Cancer;   Kidney Cancer;   Kidney Neoplasms;   Renal Cancer;   Renal Neoplasms Intervention:   Drug: Nivolumab Sponsor:   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS The constructed siRNA expression vectors can effectively suppress the expression of HIF-2α and P-gp, which then can reverse the chemotherapy resistance of A549 cells. PMID: 29469087 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
This study sought to determine changes in practice patterns for treatment of stage IA non–small cell lung cancer (NSCLC) after the introduction of SABR into the United States. This population-based study also examined changes in survival during this time period for all patients and specifically for patients treated with RT, surgery, or observation. Methods: We included patients in the Surveillance, Epidemiology, and End Results database diagnosed with stage IA NSCLC diagnosed between 2004 and 2012. Changes in treatment patterns were assessed. Outcomes were compared across 2 time periods: 2004 to 2008 (pre-SABR) an...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Thoracic Source Type: research
In spite of the growing body of data from prospective randomized clinical trials (PRCTs) and meta-analyses, the optimal treatment approach in patients with stage IIIA non–small cell lung cancer remains unknown. This review focuses on the available data directly confronting induction chemotherapy or induction radiochemotherapy (RT-CHT) when followed by surgery with exclusive RT-CHT. Seven PRCTs and 4 meta-analyses investigated this issue. In addition, numerous retrospective studies attempted to identify potential predictors and/or prognosticators that may have influenced the decision to offer surgery in a particular p...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Review Article: Thoracic Source Type: research
Authors: Re MD, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S, Maio MD, Petrini I, Danesi R Abstract Rationale: KRAS is the most common and, simultaneously, the most ambiguous oncogene implicated in human cancer. Despite KRAS mutations were identified in Non Small Cell Lung Cancers (NSCLCs) more than 20 years ago, selective and specific inhibitors aimed at directly abrogating KRAS activity are not yet available. Nevertheless, many therapeutic approaches have been developed potentially useful to treat NSCLC patients mutated for KRAS and refractory to both standard chemotherapy and targeted therapies.The focus ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Thakur C, Rapp UR, Rudel T Abstract Identifying metastatic tumor growth at an early stage has been one of the biggest challenges in the treatment of lung cancer. By genetic lineage tracing approach in a conditional model of Non-Small Cell Lung Cancer (NSCLC) in mice, we demonstrate that cystic lesions represent an early stage of metastatic invasion. We generated a mouse model for NSCLC which incorporated a heritable DsRed fluorescent tag driven by the ubiquitous CAG promoter in the alveolar type II cells of the lung. We found early cystic lesions in a secondary organ (liver) that lacked the expression of b...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Immunotherapy,Volume 10, Issue 5, Page 403-410, April 2018.
Source: Immunotherapy - Category: Allergy & Immunology Authors: Source Type: research
Conclusion LJSJF exerts more pronounced cytotoxic effects against NSCLC cells than SB does by synergistically regulating the underlining molecular mechanisms including EGFR and/or p53 signaling pathways. Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Conferences | Internal Medicine | Non-Small Cell Lung Cancer | Pathology | Radiology | Respiratory Medicine